Skip to main content
. 2018 May 14;128(6):2600–2612. doi: 10.1172/JCI98709

Figure 7. Protection from TZD’s cardiovascular side effects in 2KR mice.

Figure 7

(A–D) Heart weight normalized to femur length (A), wall thickness (B and C), and FS (D) determined by echocardiography in male mice that were on HFD feeding for 16 weeks, then were treated with Rosi for 24 weeks. *P < 0.05; **P < 0.01. n = 7 WT (vehicle); n = 7 2KR (vehicle); n = 7 WT (Rosi); n = 8 2KR (Rosi). (Please note that 1 in WT Rosi group died during echocardiographical measurement). (E) Representative M-mode echocardiographic images of left ventricular dimensions. (F) qPCR measurement of cardiac lipid-handling gene expression in above male mice. #P < 0.05; ##P < 0.01 for WT vehicle vs. WT Rosi mice. *P < 0.05; **P < 0.01 for WT vs. 2KR mice under the same treatment. n = 6 WT (vehicle); n = 6 2KR (vehicle); n = 6 WT (Rosi); n = 6 2KR (Rosi). (G) Fluid body composition changes in male mice during early treatment of Rosi. Rosi treatment was started at 8 weeks of HFD feeding. *P < 0.05; **P < 0.01. n = 8 WT; n = 8 2KR. (H) Hematocrit determined by an automated blood cell counter in male mice after 24 week of Rosi treatment. **P < 0.01. n = 7 WT (vehicle); n = 7 2KR (vehicle); n = 7 WT (Rosi); n = 8 2KR (Rosi). Data represent mean ± SEM. Student’s t test was used for statistical analyses.